Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P15088 (
mast cell
)
14,925
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The concept of
mast cell
heterogeneity has been studied extensively. Recently developed techniques to enzymatically disperse skin mast cells from human skin have shown that skin mast cells are somehow different from those of other organs such as lung and intestine. In this report, we have isolated and partially purified human skin mast cells from human neonatal foreskins by collagenase and hyaluronidase digestion. These mast cells are morphologically intact by histological, immunohistochemical and electron microscopic criteria. These human skin mast cells secrete histamine significantly (max. net histamine release, 20-30%) in a dose-related, temperature- and time-dependent fashion following stimulation with purified human C5a and C3a (over the ranges of 5 x 10(-8) M to 10(-7) M and 3 x 10(-7) M to 6 x 10(-6) M, respectively). On the other hand, interactions between human skin mast cells and other leukocytes have long been suspected of playing a very important role in cutaneous inflammation. Recently, a human neutrophil-derived histamine-releasing activity termed
HRA
-N was partially purified.
HRA
-N has been shown to cause human and rat basophil leukemia cells to degranulate. This study was also undertaken to assess the ability of
HRA
-N to directly induce histamine release from isolated human skin mast cells.
HRA
-N causes dose- and time-dependent histamine release as do human anaphylatoxins. These results suggest that
HRA
-N may lead to a better comprehension of allergic and inflammatory reactions and their modulation in the skin.
...
PMID:The effect of human anaphylatoxins and neutrophils on histamine release from isolated human skin mast cells. 137 10